+91-8668442535
Home / Biotechnology / Antinuclea

Antinuclear Antibody Testing (ANA) Market By Product Type (Reagents & Assay Kits, Software & Services, Systems), By Technique Type (Elisa, Immunofluorescence Assay, Multiplex Assay), By Disease Type (Rheumatoid Arthritis, Scleroderma, Systemic Lupus Erythematosus, Sjögren’s Syndrome, Other Diseases) - Growth, Share, Opportunities & Competitive Analysis, 2017 - 2025

According to the American Autoimmune Related Diseases Association (AARDA), autoimmune diseases affect around 50 million Americans. It is considered one of the leading causes of mortality in young and middle-aged women in the United States. An autoimmune disease occurs when the body's own cells are identified as foreign elements, and the immune system reacts against the "self" cells. Antibody testing is used to evaluate this disorder that affects tissues and organs throughout the systemic body. The global anti-nuclear antibody (ANA) testing market exhibits rapid growth due to the rising prevalence of autoimmune disorders and demand for advanced test kits. The availability of novel biomarkers and the high adoption rate of multiplex assay kits further fuel the demand for the global anti-nuclear antibody testing market.

The report titled "Antinuclear Antibody Tests Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall anti-nuclear antibody test market, along with the market's size and estimates for the duration of 2015–2025. The said research study covers an in-depth analysis of multiple market segments based on the type of product, technique, disease, and different geographies. The product types studied for analyzing the overall global anti-nuclear antibody test market are majorly segmented into reagents and assay kits, software and services, and systems. The global market for anti-nuclear antibody tests is segmented by technique type into ELISA, immunofluorescence assay, and multiplex assay. By disease, the global market for anti-nuclear antibody tests is segmented into rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, scleroderma, and other diseases.

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year. The further cross-sectional analysis presented in terms of product, technique, disease, and constituent region or country-level markets is also included in this section.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global anti-nuclear antibody testing market. Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the competitive scenario of the global anti-nuclear antibody tests market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global anti-nuclear antibody testing market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.

Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the vascular grafts market. The key players profiled in this report are Alere Inc., EUROIMMUN AG, ERBA Diagnostics, Inc., Trinity Biotech plc, Bio-Rad Laboratories, Inc., Immuno Concepts, Thermo Fisher Scientific, Inc., Antibodies, Inc., Inova Diagnostics, Zeus Scientific, Inc., and others.

Based on the type of products, the global market for anti-nuclear antibody tests is segmented as follows:

  • Reagents and Assay Kits
  • Software & Services
  • Systems

In 2016, reagents and assay kits occupied the largest share of the global anti-nuclear antibody test market. The prevalence of autoimmune disease and reagent rental agreements are driving growth in this segment. Clinical laboratories are benefiting from reagent rentals and cost-per-test contracts in terms of cost containment, which would further help them to buy new instruments. Multiplex ANA kits have emerged as the most convenient method in recent years, resulting in faster diagnosis outcomes.

Based on the type of technique, the global market for anti-nuclear antibody tests is segmented as follows:

  • Elisa
  • Immunofluorescence Assay
  • Multiplex Assay

The prevalence of autoimmune disorders is rising, owing primarily to increased public awareness of the disease and improved diagnostic tools. The global anti-nuclear antibody test market is dominated by the Enzyme-Linked Immunosorbent Assay (ELISA). The two most common ANA screening tests, indirect immunofluorescence and ELISA, are frequently practiced in commercial labs. Though ELISA is most frequently used, there is a paradigm shift observed toward the use of multiplex immunoassays. The high adoption of multiplex immunoassays by companies and laboratories drives the fast growth of this segment.

Based on the types of diseases, the global market for anti-nuclear antibody tests is segmented as follows:

  • Rheumatoid Arthritis
  • Systemic lupus erythematosus
  • Sjögren's Syndrome
  • Scleroderma
  • Other Diseases

Lately, the prevalence of autoimmune diseases, particularly in developed countries, has increased exponentially. The rapid rise in autoimmune disease prevalence is associated with major environmental factors such as infection, ecology, and nutrition. Rheumatoid arthritis occupies the largest revenue share of the global antibody tests market due to the rising prevalence of this disease. According to WHO studies, the prevalence of rheumatoid arthritis ranges from 0.3% to 1% and is commonly observed in women and developed countries. According to a Lupus Foundation of America study, approximately 1.5 million Americans have lupus, as do at least 5 million people worldwide.

For the purpose of this study, the global market for anti-nuclear antibody tests is geographically categorized into:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • Rest of Asia
  • Latin America
  • Brazil
  • Mexico
  • rest of Latin America
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of the Middle East and Africa

In 2016, North America dominated the global market for anti-nuclear antibody tests, followed by Europe. The rising incidence of autoimmune diseases, increasing healthcare expenditure, extensive research and development for novel biomarkers, and favorable reimbursement policies are some of the major factors that fuel the growth of the anti-nuclear antibody testing market in North America. Autoimmune disorders affect approximately 3% of the population in the United States. Asia Pacific is anticipated to be the fastest-growing market in the forecast period of 2017–2025. An increase in the incidence of chronic autoimmune diseases such as rheumatoid arthritis, rising awareness about the disease, improved diagnostics technology, improved healthcare infrastructure, and government funding are contributing to the growth of the anti-nuclear antibody tests market in the Asia Pacific.

Frequently Asked Questions:

The market for Antinuclear Antibody Testing (ANA) is expected to reach US$ 649 Mn in 2025.

The Antinuclear Antibody Testing (ANA) market is expected to see significant CAGR growth over the coming years, at 9.8%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Alere Inc.,Abbott Laboratories,Antibodies Inc.,Bio-Rad Laboratories Inc.,Biocom Biotech are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Jul 2017
Category:  Biotechnology
Report ID:   58594
Report Format:   PDF
Pages:   120
Rating:    4.5 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support